Table 2.

Expression of GPC3 in HCC tissue, quantification of serum-soluble GPC3, and GPC3-specific CTL induction in HCC patients

AgeGenderState of tumor*GPC3 expressionSerum GPC3HLA expression§CTL induction
HLA-A2 (A*0201)–positive patients
    Pt-A2-180FIIIa++++
    Pt-A2-272MII++++
    Pt-A2-367FIIND+ND+
    Pt-A2-454MI+++
    Pt-A2-557MINDND
    Pt-A2-666MI+
    Pt-A2-754MIIIa++
    Pt-A2-873MIINDND+
    Pt-A2-968FIIIa++
    Pt-A2-1054MII+++
HLA-A24 (A*2402)-positive patients
    Pt-A24-160MIVa++++
    Pt-A24-257MIVa+++
    Pt-A24-375FIIIa++++
    Pt-A24-459MIIIaNDND+
    Pt-A24-552MIVb+
    Pt-A24-665MIND+ND+
    Pt-A24-761MINDND+
    Pt-A24-874MIINDND
    Pt-A24-959MIVb
    Pt-A24-1069MIVa+++
    Pt-A24-1172MII+
    Pt-A24-1261MIIIa++++
  • Abbreviations: F, female; M, male; ND, not determined.

  • * Tumor-node-metastasis classification.

  • Positive (+) or negative (−) staining of tumor cells in contrast with peritumor normal tissue as background staining.

  • Serum levels >106 ng/mL were evaluated as positive.

  • § Immunohistochemical staining of the membrane of tumor cells was evaluated as positive.

  • Specific lytic activity (≧20%) at E:T ratio = 20 against HepG2 target cells was evaluated as positive by 51Cr release assay.